Sanofi's Beyfortus RSV Antibody Sales Rise 9.5% to €1.8 Billion
Sanofi's joint RSV antibody Beyfortus with AstraZeneca generated €1.8 billion in 2025 sales, marking a 9.5% year-over-year increase. This performance contrasts with Merck’s Enflonsia $21 million Q4 sales, highlighting Sanofi’s stronger position in the competitive RSV prophylaxis market.
1. Beyfortus Sales Growth
In 2025, AstraZeneca and Sanofi’s RSV antibody Beyfortus achieved €1.8 billion in global sales, a 9.5% year-over-year increase driven by strong uptake in infant immunization programs across North America and Europe.
2. Competitive Landscape
Beyfortus competes directly with Merck’s Enflonsia, which recorded $21 million in Q4 2025, as well as Pfizer’s Abrysvo, GSK’s Arexvy and Moderna’s mRESVIA, intensifying the battle for RSV prophylaxis market share.
3. Outlook for Sanofi
With Enflonsia under EU review and potential inventory corrections in Merck’s channel, Sanofi is positioned to expand Beyfortus uptake in 2026, contingent on maintaining distribution efficiency and supporting vaccination rates.